Evaluation of the efficiency of metabolic therapy in elderly patients with carbohydrate metabolism disorders after ischemic stroke
DOI: https://doi.org/10.29296/25877305-2020-03-15
Issue:
3
Year:
2020
The objective of this open-label randomized controlled study was to investigate the time course of changes in the parameters of carbohydrate and lipid metabolisms and in the concentration of N-terminal pro b-type natriuretic peptide (NT-proBNP), a marker for heart failure, in elderly patients who had experienced primary or secondary ischemic stroke treated with Mildronate 1000 mg/day added to the standard therapy cycle. Subjects and methods. The investigation enrolled 60 patients aged 60 to 90 years who had experienced a primary or secondary ischemic stroke in 2019. All the patients selected for this investigation were randomized into two groups. In Group 1 (n=30), the standard therapy was added by Mildronate as 500-mg capsules twice daily for 12 weeks; in Group 2 (n=30) Mildronate was not used. All the included patients underwent a double study of blood biochemical parameters: glucose, cholesterol, LDL-cholesterol, HLD-cholesterol, triglycerides, ALT, AST, creatinine, high-sensitivity C-reactive protein (hs-CRP), NT-proBNP, glycated hemoglobin (HbA1c) at the beginning and completion of the treatment cycle. The follow-up period was 12 weeks. All the patients included in the study received therapy that included secondary prevention of stroke and correction using antihypertensive, lipid-lowering, antiplatelet, anticoagulant, and hypoglycemic therapies for all currently existing concomitant diseases. Results. Group 1, in which Mildronate 1000 mg per day was added to the therapy for 12 weeks, showed a significant decrease in the parameters: glucose, glycated hemoglobin, triglycerides, ALT, AST and brain natriuretic peptide. The levels of cholesterol, LDL-cholesterol, atherogenic index, CRP, and creatinine decreased in Group 1, and, on the contrary, the concentration of HDL-cholesterol increased; however, these changes did not reach statistical significance at the end of the follow-up. In the control group, no significant changes were found in the biochemical parameters under study. Conclusion. This open-label randomized controlled study has led to the conclusion that Mildronate can have a positive effect on the parameters of carbohydrate and lipid metabolisms and improve myocardial and hepatic functions in elderly patients after a primary or secondary ischemic stroke.
Keywords:
carbohydrate and lipid disorders
Mildronate
ischemic stroke
rehabilitation
References:
- Grinin V.M., Shestemirova E.I., Demograficheskoe starenie v Rossii na sovremennom etape // Vestnik RAMN. – 2015; 70 (3): 348–54 [Grinin V.M., Shestemirova E.I. Demographic Ageing in Russia at the Present Stage // Vestnik RAMN. – 2015; 70 (3): 348–54 (in Russ.)]. DOI: 10.15690/vramn.v70i3.1332
- Oganov R.G., Simanenkov V.I., Bakulin I.G. i dr. Komorbidnaja patologija v klinicheskoj praktike. Algoritmy diagnostiki i lechenija. Klinicheskie rekomendatsii // Kardiovaskuljarnaja terapija i profilaktika. – 2019; 18 (1): 5–66 [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment // Cardiovascular Therapy and Prevention. – 2019; 18 (1): 5–66 (in Russ.)]. https://doi.org/10.15829/1728-8800-2019-1-5-66
- Putilina M.V. Komorbidnost' u patsientov pozhilogo vozrasta // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2016; 116 (5): 106–11 [Putilina M.V. Comorbidity in elderly patients // S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. – 2016; 116 (5): 106–11 (in Russ.)]. https://doi.org/10.17116/jnevro201611651106-111
- Shishkova V.N. Komorbidnost' i poliprogmazija: fokus i tsitoprotektsiju // Consilium Medicum. – 2016; 18 (12): 73–9 [Shishkova V.N. Comorbidity and polypharmacy: focus on cytoprotection // Consilium Medicum. – 2016; 18 (12): 73–9 (in Russ.)]. DOI: 10.26442/2075-1753_2016.12.73-79
- Degrace P., Demizieux L., Du Z. et al. Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats // J. Biol. Chem. – 2007; 282: 20816–26. DOI: 10.1074/jbc.M611391200
- Liepinsh E., Vilskersts R., Zvejniece L. et al. Protective effects of mildronate in an experimental model of type 2 diabetesingoto-kakizaki rats // Br. J. Pharmacol. – 2009; 157: 1549–56. DOI: 10.1111/j.1476-5381.2009.00319.x
- Sokolovska J., Isajevs S., Sugoka O. et al. Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocindiabetes mellitus model // Cell Biochem. Funct. – 2011; 29: 55–63. DOI: 10.1002/cbf.1719
- Sokolovska J., Rumaks J., Karajeva N. et al. The influence of mildronate on peripheral neuropathy and somecharacteristics of glucose and lipid metabolism in rat streptozotocin-induceddiabetes mellitus model // Biomed. Khim. – 2011; 57: 490–500. DOI: 10.18097/pbmc20115705490
- Liepinsh E., Skapare E., Svalbe B. et al. Anti-diabetic effects of mildronate alone or in combination with metformin inobesezucker rats // Eur. J. Pharmacol. – 2011; 658: 277–83. DOI: 10.1016/j.ejphar.2011.02.019
- Sychev A.S., Tsaregorodtsev S.V., Kebina A.L. i dr. Effektivnost' primenenija mel'donija v kompleksnom lechenii patsientov s dekompensatsiej hronicheskoj serdechnoj nedostatochnosti // Lechaschij vrach. – 2019; 2: 11–5 [Sycheva A.S., Tsaregorodtsev S.V., Kebina A.L. et al. Efficiency of meldonium application in complex treatment of patients with chronic heart failure decompensation // Lechashchii vrach. – 2019; 2: 11–5 (in Russ.)].
- Shishkova V., Zotova L., Maljukova N. Vozmozhnost' povyshenija effektivnosti rannej kompleksnoj reabilitatsii u patsientov s postinsul'tnoj afaziej // Vrach. – 2018; 29 (6): 39–44 [Shishkova V., Zotova L., Malyukova N. The possibility of enhancing the efficiency of early comprehensive rehabilitation in patients with poststroke aphasia // Vrach. – 2018; 29 (6): 39–44 (in Russ.)]. https://doi.org/10.29296/25877305-2018-06-08
- Shishkova V.N. Novye vozmozhnosti otsenki effektivnosti vtorichnoj profilaktiki ishemicheskogo insul'ta v terapevticheskoj praktike // Consilium Medicum. – 2019; 21 (2): 43–7 [Shishkova V.N. New opportunities of evaluation of ischemic stroke secondary prophylaxis effectiveness in therapeutic practice // Consilium Medicum. – 2019; 21 (2): 43–7 (in Russ.)]. DOI: 10.26442/20751753.2019.2.190216
- Vertkin A.L., Hovasova N.O., Pshenichnikova V.V. i dr. Mel'donij: effektivnye tochki primenenija // Kardiovaskuljarnaja terapija i profilaktika. – 2013; 12 (2): 94–7 [Vertkin A.L., Khovasova N.O., Pshenichnikova V.V., et al. Meldonium: effective action points // Cardiovascular Therapy and Prevention. – 2013; 12 (2): 94–7 (in Russ.)]. https://doi.org/10.15829/1728-8800-2013-2-94-97
- Smirnova M.D., Svirida O.N., Ageev F.T. i dr. Ispol'zovanie mel'donija dlja uluchshenija adaptatsii patsientov s arterial'noj gipertenziej i prediabetom k vozdejstviju zhary // Sistemnye gipertenzii. – 2015; 12 (4): 46–51 [Smirnova M.D., Svirida O.N., Ageev F.T. et al. Using meldonium to improve adaptation of patients with hypertension and pre-diabetes to influence of heat // Systemic Hypertension. – 2015; 12 (4): 46–51 (in Russ.)]. DOI: 10.26442/2075-082X_12.4.46-51
- Lobanova M.V., Poletaeva L.V. Vlijanie Mildronata na uroven' gljukozy krovi i glikirovannogo gemoglobina u bol'nyh saharnym diabetom tipa 2 // Vestnik RGMU. – 2008; 2 (61): 37 [Lobanova M.V., Poletaeva L.V. Vliyanie Mildronata na uroven’ glyukozy krovi i glikirovannogo gemoglobina u bol’nykh sakharnym diabetom tipa 2 // Vestnik RGMU. – 2008; 2 (61): 37 (in Russ.)].
- Turkina S.V. ,Poletaeva L.V., Inozemtseva M.A. Primenenie mel'donija v sostave kompleksnoj terapii u bol'nyh saharnym diabetom tipa 2 s perifericheskoj nejropatiej: rol' insulinorezistentnosti // Vestnik VolgGMU. – 2015; 2: 120–3 [Turkina S.V., Poletaeva L.V., Inozemtseva M.A. Use of meldonium in comprehensive treatment of patients with type 2 diabetes associated with peripheral neuropathy. Role of insulin resistance // Vestnik VolgGMU. – 2015; 2: 120–3 (in Russ.)].
- Statsenko M.E., Turkina S.V., Belenkova S.V. i dr. Vlijanie mildronata v sostave kombinirovannoj terapii hronicheskoj serdechnoj nedostatochnosti u bol'nyh saharnym diabetom tipa 2 na uglevodnyj, lipidnyj obmen i pokazateli oksidativnogo stressa // Ros. kardiol. zhurn. – 2010; 2: 45–51 [Statsenko M.E., Turkina S.V., Belenkova S.V. et al. Effects of mildronate, as a part of combined heart failure therapy, on carbohydrate and lipid metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus // Russian Journal of Cardiology. – 2010; 2: 45–51 (in Russ.)]. https://doi.org/10.15829/1560-4071-2010-2-45-51
- Altman D., Machin D., Bryant T. et al. Statistics with confidence / Bristol: Arrowsmith Ltd., 2005; 240 p.
- Kuzikov A.V., Bulko T.V., Masamreh R.A. i dr. Analiz vlijanija mel'donija na kataliticheskuju aktivnost' tsitohroma P450 3A4 // Vestnik RGMU. – 2016; 6: 10–5 [Kuzikov A.V., Bulko T.V., Masamrekh R.A. et al. Analysis of mildronate effect on the catalytic activity of cytochrome R450 3A4 // Vestnik RGMU. – 2016; 6: 10–5 (in Russ.)]. DOI: 10.24075/brsmu.2016-06-02